Open-Angle Glaucoma - Pipeline Review, H2 2016

Open-Angle Glaucoma - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Open-Angle Glaucoma - Pipeline Review, H2 2016’, provides an overview of the Open-Angle Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Open-Angle Glaucoma
    • The report reviews pipeline therapeutics for Open-Angle Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Open-Angle Glaucoma therapeutics and enlists all their major and minor projects
    • The report assesses Open-Angle Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Open-Angle Glaucoma
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Open-Angle Glaucoma
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Open-Angle Glaucoma pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Open-Angle Glaucoma Overview
    Therapeutics Development
    Pipeline Products for Open-Angle Glaucoma - Overview
    Pipeline Products for Open-Angle Glaucoma - Comparative Analysis
    Open-Angle Glaucoma - Therapeutics under Development by Companies
    Open-Angle Glaucoma - Therapeutics under Investigation by Universities/Institutes
    Open-Angle Glaucoma - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Open-Angle Glaucoma - Products under Development by Companies
    Open-Angle Glaucoma - Products under Investigation by Universities/Institutes
    Open-Angle Glaucoma - Companies Involved in Therapeutics Development
    Aerie Pharmaceuticals, Inc.
    Allergan Plc
    Amakem NV
    Bausch & Lomb Incorporated
    F. Hoffmann-La Roche Ltd.
    Glaukos Corporation
    Inotek Pharmaceuticals Corporation
    Isarna Therapeutics GmbH
    Kowa Company, Ltd.
    Laboratoires Thea S.A.
    Laboratorios Sophia S.A. de C.V.
    Lee's Pharmaceutical Holdings Limited
    Lexicon Pharmaceuticals, Inc.
    Ocular Therapeutix, Inc.
    Otsuka Holdings Co., Ltd.
    Oxford BioMedica Plc
    Sanofi
    Santen Pharmaceutical Co., Ltd.
    Senju Pharmaceutical Co., Ltd.
    Sun Pharma Advanced Research Company Ltd.
    Sylentis S.A.U.
    ViSci Ltd.
    Open-Angle Glaucoma - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Combination Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    (bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (bimatoprost + timolol maleate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (carteolol hydrochloride + latanoprost) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (latanoprost + netarsudil mesylate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (latanoprost + timolol maleate) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (latanoprost + trabodenoson) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMA-0076 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bamosiran - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bimatoprost - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    bimatoprost SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DE-117 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    decorin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Glaucoma-GT - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ISTH-0036 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprost - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprost - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprost SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprost SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    latanoprostene bunod - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    levobetaxolol hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LX-7101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MAN-01 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MGV-354 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    netarsudil mesylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OPA-6566 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PRO-067 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    R-801 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-4929 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ripasudil - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RO-5093151 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SAR-366234 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Sepetaprost - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SNJ-1656 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    trabodenoson - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    travoprost - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    travoprost SR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    travoprost XR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Open-Angle Glaucoma - Dormant Projects
    Open-Angle Glaucoma - Discontinued Products
    Open-Angle Glaucoma - Product Development Milestones
    Featured News & Press Releases
    Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
    Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension
    Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting
    Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week
    Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System
    Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Open-Angle Glaucoma, H2 2016
    Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Investigation by Universities/Institutes, H2 2016
    Open-Angle Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016
    Open-Angle Glaucoma - Pipeline by Allergan Plc, H2 2016
    Open-Angle Glaucoma - Pipeline by Amakem NV, H2 2016
    Open-Angle Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2016
    Open-Angle Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Open-Angle Glaucoma - Pipeline by Glaukos Corporation, H2 2016
    Open-Angle Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016
    Open-Angle Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2016
    Open-Angle Glaucoma - Pipeline by Kowa Company, Ltd., H2 2016
    Open-Angle Glaucoma - Pipeline by Laboratoires Thea S.A., H2 2016
    Open-Angle Glaucoma - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016
    Open-Angle Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
    Open-Angle Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
    Open-Angle Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2016
    Open-Angle Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
    Open-Angle Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2016
    Open-Angle Glaucoma - Pipeline by Sanofi, H2 2016
    Open-Angle Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
    Open-Angle Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016
    Open-Angle Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016
    Open-Angle Glaucoma - Pipeline by Sylentis S.A.U., H2 2016
    Open-Angle Glaucoma - Pipeline by ViSci Ltd., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Open-Angle Glaucoma - Dormant Projects, H2 2016
    Open-Angle Glaucoma - Dormant Projects (Contd..1), H2 2016
    Open-Angle Glaucoma - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Open-Angle Glaucoma, H2 2016
    Number of Products under Development for Open-Angle Glaucoma - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Assessment by Combination Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook